文献速递呼吸道感染呼吸危重症与机械通气

快速多重细菌PCR指导肺炎抗生素管理:Flagship II随机对照试验

Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of Gram-negative bacterial infection (Flagship II): a multicentre, randomised controlled trial.
PubMed 文献 · Lancet Respir Med · 2022-05-23

这项在瑞士两中心开展的随机对照试验纳入208例疑似肺炎且需支气管镜肺泡灌洗、有革兰阴性菌感染风险的患者,比较多重细菌PCR与常规微生物学指导抗生素治疗的效果。

要点

  • 两组抗菌药物相关不良事件与支气管镜相关不良事件发生率相近。

核心结论

  • 对因肺炎住院且有革兰阴性杆菌感染风险的患者,肺泡灌洗液多重细菌PCR可缩短不适当抗生素治疗时间。

研究设计与样本

  • 研究者发起的多中心随机对照试验,在瑞士巴塞尔大学医院和圣加仑州医院两个三级中心开展。
  • 纳入208例18岁以上疑似肺炎、有支气管镜肺泡灌洗临床指征且存在革兰阴性菌感染风险的患者,随机分为PCR组100例和常规微生物学对照组108例。
  • 主要结局为从支气管镜至出院或支气管镜后30天期间不适当抗生素治疗的小时数。

主要发现

  • 抗菌药物相关不良事件PCR组5例(5%)、对照组4例(4%);支气管镜相关不良事件两组各2例(1%)。
  • PCR组死亡8例(8%),对照组死亡11例(10%),所有院内死亡均归因于呼吸系统原因。

关键数值与推荐

  • PCR组在采样后约5小时给出抗生素治疗建议。
  • PCR采用Unyvero Hospitalized Pneumonia(HPN)Cartridge检测革兰阴性杆菌。

临床怎么用

  • 对疑似肺炎、有革兰阴性菌感染风险且需肺泡灌洗的患者,可考虑加做多重细菌PCR以辅助抗生素管理。
  • PCR结果约5小时可返回,有助于尽早调整不适当经验性抗生素治疗。

局限性

  • 治疗医生未设盲,仅委员会面板对随机分组设盲。
  • 研究在瑞士两个三级中心开展,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: PCR-based testing has transformed the management of suspected respiratory viral infections. We aimed to determine whether multiplex bacterial PCR of bronchoalveolar lavage fluid aids antibiotic stewardship in patients with pneumonia. METHODS: This investigator-initiated, multicentre, randomised controlled trial was conducted at two tertiary care centres in Switzerland (University Hospital of Basel and Kantonsspital St Gallen). Patients aged 18 years or older who were admitted to hospital with suspected pneumonia, had a clinical indication for bronchoscopy with bronchoalveolar lavage, and were at risk of Gram-negative bacterial infection were included. Patients were randomly assigned (1:1) to either the multiplex bacterial PCR group or the conventional microbiology control group using a random allocation sequence. Treating physicians were not masked, but the committee panel was masked to patient randomisation. All patients underwent bronchoscopy with bronchoalveolar lavage and samples were assessed by conventional microbiological culture (and additionally, in the PCR group, by multiplex bacterial PCR for Gram-negative rods using the Unyvero Hospitalized Pneumonia [HPN] Cartridge; Curetis, Holzgerlingen, Germany). Patients received empirical antibiotic therapy as clinically indicated by the treating physician. In the PCR group, a recommendation regarding antibiotic therapy was made approximately 5 h after taking the sample. The primary outcome was the time in hours on inappropriate antibiotic therapy from bronchoscopy to discharge or to 30 days after bronchoscopy. This trial was registered with the International Clinical Trials Registry Platform, ISRCTN95828556. FINDINGS: Between May 31, 2017, and Sept 25, 2019, 740 patients with pneumonia were screened for eligibility and 208 were included and randomly assigned to the PCR group (n=100) or conventional microbiology control group (n=108). The mean age of patients was 65·9 years (SD 14·0) and 135 (65%) were male. After daily follow-up until hospital discharge or for a maximum of 30 days, the duration of inappropriate antibiotic treatment was significantly shorter by 38·6 h (95% CI 19·5-57·7) in the PCR group than in the control group (adjusted mean 47·1 h [34·7-59·5] vs 85·7 h [78·8-95·6]; p<0·0001), which translates as a decrease in the duration of inappropriate antibiotic therapy of 45·0% (37·9-52·1). Adverse events due to antimicrobial therapy occurred in nine patients (five [5%] in the PCR group vs four [4%] in the control group) and due to bronchoscopy occurred in four patients (two [1%] vs two [1%]). There were eight (8%) deaths in the PCR group and 11 (10%) in the control group. All in-hospital deaths were attributed to a respiratory cause. INTERPRETATION: Multiplex bacterial PCR examination of bronchoalveolar lavage decreases the duration of inappropriate antibiotic therapy of patients admitted to hospital with pneumonia and at risk of Gram-negative rod infection. This approach warrants further consideration in future antibiotic stewardship strategies. FUNDING: Curetis and the Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital Basel, Switzerland.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Darie AM, Khanna N, Jahn K, et al. Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of Gram-negative bacterial infection (Flagship II): a multicentre, randomised controlled trial. Lancet Respir Med. 2022. PMID: 35617987. doi:10.1016/S2213-2600(22)00086-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。